IL219279A0 - Corticosteroid and anti-cd56-maytansinoid conjugate dosing regimens and uses thereof - Google Patents
Corticosteroid and anti-cd56-maytansinoid conjugate dosing regimens and uses thereofInfo
- Publication number
- IL219279A0 IL219279A0 IL219279A IL21927912A IL219279A0 IL 219279 A0 IL219279 A0 IL 219279A0 IL 219279 A IL219279 A IL 219279A IL 21927912 A IL21927912 A IL 21927912A IL 219279 A0 IL219279 A0 IL 219279A0
- Authority
- IL
- Israel
- Prior art keywords
- corticosteroid
- dosing regimens
- maytansinoid conjugate
- conjugate dosing
- maytansinoid
- Prior art date
Links
- 239000003246 corticosteroid Substances 0.000 title 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
- A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/77—Internalization into the cell
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Immunology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Epidemiology (AREA)
- General Chemical & Material Sciences (AREA)
- Genetics & Genomics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Hematology (AREA)
- Engineering & Computer Science (AREA)
- Oncology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US25380409P | 2009-10-21 | 2009-10-21 | |
| PCT/US2010/053579 WO2011050180A1 (en) | 2009-10-21 | 2010-10-21 | Novel dosing regimen and method of treatment |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| IL219279A0 true IL219279A0 (en) | 2012-06-28 |
Family
ID=43898626
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| IL219279A IL219279A0 (en) | 2009-10-21 | 2012-04-19 | Corticosteroid and anti-cd56-maytansinoid conjugate dosing regimens and uses thereof |
Country Status (13)
| Country | Link |
|---|---|
| US (1) | US20110097345A1 (OSRAM) |
| EP (1) | EP2490715A4 (OSRAM) |
| JP (1) | JP2013508400A (OSRAM) |
| KR (1) | KR20120094472A (OSRAM) |
| CN (1) | CN102630165A (OSRAM) |
| AU (1) | AU2010310577A1 (OSRAM) |
| BR (1) | BR112012009250A2 (OSRAM) |
| CA (1) | CA2775806A1 (OSRAM) |
| IL (1) | IL219279A0 (OSRAM) |
| IN (1) | IN2012DN02826A (OSRAM) |
| MX (1) | MX2012004406A (OSRAM) |
| RU (1) | RU2012120691A (OSRAM) |
| WO (1) | WO2011050180A1 (OSRAM) |
Families Citing this family (22)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US9486408B2 (en) | 2005-12-01 | 2016-11-08 | University Of Massachusetts Lowell | Botulinum nanoemulsions |
| AU2011207362B2 (en) * | 2010-01-21 | 2013-10-17 | Immunogen, Inc. | Compositions and methods for treatment of ovarian cancer |
| EP2524929A1 (en) * | 2011-05-17 | 2012-11-21 | Sanofi | Use of anti-CD19 maytansinoid immunoconjugate antibody for the treatment of CD19+ B-cell malignancies syptoms |
| WO2014018563A2 (en) * | 2012-07-23 | 2014-01-30 | The Board Of Trustees Of The Leland Stanford Junior University | Methods for the treatment of cancer |
| WO2014052876A1 (en) * | 2012-09-28 | 2014-04-03 | Immunogen Inc. | Methods for increasing efficacy of cd56- based therapy |
| WO2014089177A2 (en) | 2012-12-04 | 2014-06-12 | Massachusetts Institute Of Technology | Compounds, conjugates and compositions of epipolythiodiketopiperazines and polythiodiketopiperazines |
| SG11201509043RA (en) * | 2013-05-14 | 2015-12-30 | Immunogen Inc | Anti-folr1 immunoconjugate dosing regimens |
| LT3055332T (lt) * | 2013-10-08 | 2020-04-10 | Immunogen, Inc. | Anti-folr1 imunokonjugato dozavimo režimai |
| CN106456748A (zh) | 2014-01-08 | 2017-02-22 | 小利兰·斯坦福大学托管委员会 | 小细胞肺癌的靶向疗法 |
| AU2015282627B2 (en) | 2014-06-30 | 2020-04-02 | Glykos Finland Oy | Saccharide derivative of a toxic payload and antibody conjugates thereof |
| US10918627B2 (en) | 2016-05-11 | 2021-02-16 | Massachusetts Institute Of Technology | Convergent and enantioselective total synthesis of Communesin analogs |
| JP6998938B2 (ja) * | 2016-08-10 | 2022-02-04 | セルジーン クオンティセル リサーチ，インク． | 再発性および／または難治性の固形腫瘍および非ホジキンリンパ腫の処置 |
| KR102487144B1 (ko) | 2016-11-21 | 2023-01-12 | 에이리온 테라퓨틱스, 인코포레이티드 | 큰 물질의 경피 전달 |
| WO2018209239A1 (en) | 2017-05-11 | 2018-11-15 | Massachusetts Institute Of Technology | Potent agelastatin derivatives as modulators for cancer invasion and metastasis |
| US10640508B2 (en) | 2017-10-13 | 2020-05-05 | Massachusetts Institute Of Technology | Diazene directed modular synthesis of compounds with quaternary carbon centers |
| AU2019294510A1 (en) * | 2018-06-26 | 2021-01-21 | Immunogen, Inc. | Immunoconjugates targeting ADAM9 and methods of use thereof |
| US11535634B2 (en) | 2019-06-05 | 2022-12-27 | Massachusetts Institute Of Technology | Compounds, conjugates, and compositions of epipolythiodiketopiperazines and polythiodiketopiperazines and uses thereof |
| US20230322933A1 (en) * | 2020-06-04 | 2023-10-12 | Bioinvent International Ab | Model for prediction of tolerability issues in connection with intravenous administration of therapeutic antibodies |
| US12030888B2 (en) | 2021-02-24 | 2024-07-09 | Massachusetts Institute Of Technology | Himastatin derivatives, and processes of preparation thereof, and uses thereof |
| WO2024230793A1 (en) * | 2023-05-10 | 2024-11-14 | Nanjing Legend Biotech Co., Ltd. | Chimeric antigen receptors and methods of use thereof |
| CN120053673A (zh) * | 2025-02-11 | 2025-05-30 | 暨南大学 | 纳米前药及其制备方法和用途 |
| CN120173115A (zh) * | 2025-05-20 | 2025-06-20 | 苏州欣协生物科技有限公司 | 一种抗人cd56蛋白工程抗体及其制备方法 |
Family Cites Families (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5208020A (en) * | 1989-10-25 | 1993-05-04 | Immunogen Inc. | Cytotoxic agents comprising maytansinoids and their therapeutic use |
| US5639641A (en) * | 1992-09-09 | 1997-06-17 | Immunogen Inc. | Resurfacing of rodent antibodies |
| US7303749B1 (en) * | 1999-10-01 | 2007-12-04 | Immunogen Inc. | Compositions and methods for treating cancer using immunoconjugates and chemotherapeutic agents |
| EP2266607A3 (en) * | 1999-10-01 | 2011-04-20 | Immunogen, Inc. | Immunoconjugates for treating cancer |
| MXPA03012022A (es) * | 2001-09-20 | 2005-07-01 | Cornell Res Foundation Inc | Metodos y composiciones para tratar o prevenir padecimientos de la piel, utilizando agentes de enlace especificos para el antigeno de membrana especifico de prostata. |
| US20040126379A1 (en) * | 2002-08-21 | 2004-07-01 | Boehringer Ingelheim International Gmbh | Compositions and methods for treating cancer using cytotoxic CD44 antibody immunoconjugates and chemotherapeutic agents |
| CN1816356A (zh) * | 2003-05-14 | 2006-08-09 | 免疫原公司 | 药物缀合物组合物 |
| WO2005000230A2 (en) * | 2003-06-05 | 2005-01-06 | Charles Achkar | Methods of treating hyperproliferative cell disorders |
| US8101720B2 (en) * | 2004-10-21 | 2012-01-24 | Xencor, Inc. | Immunoglobulin insertions, deletions and substitutions |
| ZA200708694B (en) * | 2005-04-15 | 2009-01-28 | Immunogen Inc | Elimination of heterogeneous or mixed cell population in tumors |
| NZ576122A (en) * | 2006-09-26 | 2012-09-28 | Genmab As | Anti-cd38 plus corticosteroids plus a non-corticosteroid chemotherapeutic for treating tumors |
| AU2009271401A1 (en) * | 2008-06-16 | 2010-01-21 | Immunogen Inc. | Novel synergistic effects |
| AU2011207362B2 (en) * | 2010-01-21 | 2013-10-17 | Immunogen, Inc. | Compositions and methods for treatment of ovarian cancer |
| WO2012138537A1 (en) * | 2011-04-01 | 2012-10-11 | Immunogen, Inc. | Compositions and methods for treatment of ovarian, peritoneal, and fallopian tube cancer |
-
2010
- 2010-10-21 WO PCT/US2010/053579 patent/WO2011050180A1/en not_active Ceased
- 2010-10-21 EP EP10825683.5A patent/EP2490715A4/en not_active Withdrawn
- 2010-10-21 CN CN2010800455971A patent/CN102630165A/zh active Pending
- 2010-10-21 BR BR112012009250A patent/BR112012009250A2/pt not_active IP Right Cessation
- 2010-10-21 IN IN2826DEN2012 patent/IN2012DN02826A/en unknown
- 2010-10-21 JP JP2012535373A patent/JP2013508400A/ja not_active Withdrawn
- 2010-10-21 AU AU2010310577A patent/AU2010310577A1/en not_active Abandoned
- 2010-10-21 US US12/909,697 patent/US20110097345A1/en not_active Abandoned
- 2010-10-21 MX MX2012004406A patent/MX2012004406A/es not_active Application Discontinuation
- 2010-10-21 RU RU2012120691/15A patent/RU2012120691A/ru unknown
- 2010-10-21 KR KR1020127008847A patent/KR20120094472A/ko not_active Withdrawn
- 2010-10-21 CA CA2775806A patent/CA2775806A1/en not_active Abandoned
-
2012
- 2012-04-19 IL IL219279A patent/IL219279A0/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| US20110097345A1 (en) | 2011-04-28 |
| IN2012DN02826A (OSRAM) | 2015-07-24 |
| KR20120094472A (ko) | 2012-08-24 |
| MX2012004406A (es) | 2012-05-08 |
| AU2010310577A1 (en) | 2012-04-19 |
| CN102630165A (zh) | 2012-08-08 |
| EP2490715A4 (en) | 2013-06-26 |
| CA2775806A1 (en) | 2011-04-28 |
| RU2012120691A (ru) | 2013-11-27 |
| BR112012009250A2 (pt) | 2017-06-20 |
| WO2011050180A1 (en) | 2011-04-28 |
| EP2490715A1 (en) | 2012-08-29 |
| JP2013508400A (ja) | 2013-03-07 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IL219279A0 (en) | Corticosteroid and anti-cd56-maytansinoid conjugate dosing regimens and uses thereof | |
| IL256921A (en) | Pyrazolopyrimidines, pharmaceutical preparations containing them and their use | |
| SG10201801503XA (en) | e-POLYLYSINE CONJUGATES AND USE THEREOF | |
| PT2272339E (pt) | Métodos e composições para utilização com dispensadores de gel | |
| ZA201204480B (en) | Conjugate with target-finding ligand and use thereof | |
| IL218502A0 (en) | Actriib antagonists and dosing and uses thereof | |
| ZA201206449B (en) | Pyrrolobenzodiazepines and conjugates thereof | |
| ZA201200722B (en) | Pharmaceutical composition and administrations thereof | |
| EP2552953A4 (en) | FRIZZLED-BINDING SUBSTANCES AND ITS USES | |
| IL222930A0 (en) | Chlorotoxin variants, conjugates and methods for their use | |
| ZA201109034B (en) | Aminopyrrolidinone derivatives and uses thereof | |
| PL2796150T3 (pl) | Nowe koniugaty oligonukleotydowe i ich zastosowanie | |
| PL2451328T3 (pl) | Urządzenie mieszające | |
| IL213974A0 (en) | Isoxazole-isoxazole and isoxazole-isothiazole derivatives | |
| EP2467162A4 (en) | THERAPEUTIC PROCESSES AND RELATED COMPOSITIONS | |
| GB2502460B (en) | Composition and pyrotechnic device | |
| ZA201200079B (en) | Pharmaceutical compositions and solid forms | |
| GB0902429D0 (en) | Compositions and their use | |
| GB0920125D0 (en) | Delivery device and delivery methods | |
| EP2461870A4 (en) | THERAPEUTIC COMPOSITIONS AND METHOD | |
| ZA201200260B (en) | Polyphenylsulphone-polytetrafluroethylene compositions and use thereof | |
| GB2502459B (en) | Composition and pyrotechnic device | |
| GB0909944D0 (en) | Therapeutic agent and assay | |
| GB0910620D0 (en) | Agents and uses thereof | |
| GB0905558D0 (en) | Pharmaceutical agent |